These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 7962990)

  • 1. Beta-lactamases: current situation and clinical importance.
    Garau J
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S5-9. PubMed ID: 7962990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing beta-lactamases of Gram-negative extraintestinal clinical isolates.
    Gál Z; Szabó D; Kovács P; Hernádi F; Tóth-Martinez B; Rozgonyi F
    Int J Antimicrob Agents; 2000 Dec; 16(4):395-400. PubMed ID: 11118847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.
    Neu HC
    Am J Med; 1985 Nov; 79(5B):2-12. PubMed ID: 3907341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.
    Sanders CC; Sanders WE
    Clin Infect Dis; 1992 Nov; 15(5):824-39. PubMed ID: 1445981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of resistance in gram-negative bacteria: a risk of broad-spectrum beta-lactam use.
    Dworzack DL
    Drug Intell Clin Pharm; 1986; 20(7-8):562-7. PubMed ID: 3488894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical importance of inducible beta-lactamases in gram-negative bacteria.
    Sanders CC; Sanders WE
    Eur J Clin Microbiol; 1987 Aug; 6(4):435-8. PubMed ID: 3311737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance.
    Neu HC; Chin NX
    Chemioterapia; 1985 Feb; 4(1):63-70. PubMed ID: 3872725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sch 34343, in-vitro antibacterial activity and beta-lactamase stability.
    Stobberingh EE; Houben AW; van Boven CP
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():73-83. PubMed ID: 3875605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation].
    Martínez-Martínez L; Calvo J
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():25-31. PubMed ID: 21130927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
    Cullmann W; Dick W; Stieglitz M; Opferkuch W
    Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.